Donald Trump blasts CEO who raised drug price 5,000 percent: 'He looks like a spoiled brat'

Donald Trump.
(Image credit: Steve Pope/Getty Images)

If Martin Shkreli — the pharmaceutical CEO who faced outrage after raising the price of a life-saving medication from $13.50 a pill to $750 — is looking for solace, he won't find any from Donald Trump.

"He looks like a spoiled brat to me," the Republican presidential frontrunner told reporters in South Carolina on Wednesday. "You want to know the truth? He looks like a spoiled brat." In August, Shkreli's Turing Pharmaceuticals acquired the drug Daraprim, which treats taxoplasmosis. A parasitic infection, taxoplasmosis can be fatal for people with weakened immune systems caused by chemotherapy and AIDS. Shkreli said on Monday the price had to go up so the company could "turn a profit," but after backlash from advocacy groups and consumers, he announced Tuesday he changed his mind and would be lowering the cost again over the next few weeks.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Catherine Garcia, The Week US

Catherine Garcia is night editor for TheWeek.com. Her writing and reporting has appeared in Entertainment Weekly and EW.com, The New York Times, The Book of Jezebel, and other publications. A Southern California native, Catherine is a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.